Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer

被引：0
|
作者：
Orlando, Laura [1 ]
Cardillo, Anna [1 ]
Ghisini, Raffaella [1 ]
Rocca, Andrea [1 ]
Balduzzi, Alessandra [1 ]
Torrisi, Rosalba [1 ]
Peruzzotti, Giulia [1 ]
Goldhirsch, Aron [1 ]
Pietri, Elisabetta [1 ]
Colleoni, Marco [1 ]
机构：
[1] European Inst Oncol, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：76 / 76
页数：1
相关论文
共 50 条
  • [1] Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
    Orlando, Laura
    Cardillo, Anna
    Ghisini, Raffaella
    Rocca, Andrea
    Balduzzi, Alessandra
    Torrisi, Rosalba
    Peruzzotti, Giulia
    Goldhirsch, Aron
    Pietri, Elisabetta
    Colleoni, Marco
    BMC CANCER, 2006, 6 (1)
  • [2] Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
    Laura Orlando
    Anna Cardillo
    Raffaella Ghisini
    Andrea Rocca
    Alessandra Balduzzi
    Rosalba Torrisi
    Giulia Peruzzotti
    Aron Goldhirsch
    Elisabetta Pietri
    Marco Colleoni
    BMC Cancer, 6
  • [3] TRASTUZUMAB BEYOND PROGRESSION IN PATIENTS WITH HER-2/NEU POSITIVE METASTATIC BREAST CANCER
    Eralp, Yesim
    JOURNAL OF BREAST HEALTH, 2009, 5 (01): : 3 - 8
  • [4] Phase II trial of metronomic capecitabine and cyclophosphamide with lapatinib and trastuzumab in patients with HER2-positive metastatic breast cancer.
    Kang, Irene
    Spicer, Darcy V.
    Lu, Janice M.
    Groshen, Susan G.
    Tsao-Wei, Denice
    Garcia, Agustin A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide in patients with HER2-negative metastatic breast cancer
    Ohtani, S.
    Fujihara, M.
    ANNALS OF ONCOLOGY, 2015, 26 : 30 - 30
  • [6] Phase I study of sunitinib in combination with metronomic dosing of cyclophosphamide and methotrexate in patients with metastatic breast cancer
    Lyandres, L.
    Melisko, M.
    Moasser, M.
    Goga, A.
    Park, J. W.
    Rugo, H. S.
    CANCER RESEARCH, 2009, 69 (02) : 286S - 286S
  • [7] Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy
    Nunes, Raquel A.
    Li, Xiaochun
    Kang, Soonmo Peter
    Burstein, Harold
    Roberts, Lisa
    Carney, Walter
    Blackwell, Kimberly
    Ryan, Paula
    Borges, Virginia
    Iglehart, J. Dirk
    Friedman, Paula
    Harris, Lyndsay N.
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2009, 24 (01): : 1 - 10
  • [8] Trastuzumab use beyond progression on previous trastuzumab treatment in HER-2 positive metastatic breast cancer
    Hutka, Margaret M.
    Kolosza, Zofia
    Utracka-Hutka, Beata
    ANNALS OF ONCOLOGY, 2007, 18 : 163 - 163
  • [9] Lapatinib plus trastuzumab for HER-2 positive metastatic breast cancer: experience of use
    Garcia Munoz, C.
    Cortijo Cascajares, S.
    Canamares Orbis, I.
    Goyache Goni, M. D. P.
    Ferrari Piquero, J. M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 892 - 893
  • [10] Evaluation of first-line trastuzumab in combination with epirubicin/cyclophosphamide for patients with HER2-positive metastatic breast cancer.
    Unich, M.
    Tjulandin, S.
    Jonat, W.
    Meerpohl, H.
    Lichinitser, M.
    Manikhas, G. M.
    Janicke, F.
    Muscholl, M.
    Pausehinger, M.
    Thomssen, C.
    Leide, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S185 - S186
12345